ADMET & PK
Colin
Bright directs Argenta’s ADMET and PK team,
who work closely with our chemistry
and biology teams, providing essential
information on the vulnerability of compounds to help direct
medicinal chemistry activities.
Our approach is to address ADMET as early as appropriate
in the discovery process, and we provide a cascade of approaches
ranging from early in vitro assessment to in
vivo pharmacokinetics.
Our in vitro assays include:
- Solubility (thermodynamic and kinetic methods)
- Physicochemical properties (logP, logD, pKa using Sirius
PCS101)
- Chemical stability
- Metabolic stability (in plasma, microsomes, S9 fraction,
cytosol and hepatocytes)
- CYP450 inhibition
- Plasma protein binding
- Permeability (IAM, PAMPA, Caco-2 and MDCK)
- Cytotoxicity/hepatotoxicity
- Metabolite identification and profiling
Our assay protocols have been developed to provide the throughput
and levels of information required for early assessment of
ADMET, but we are comfortable to run our clients' protocols
to ensure consistency.
For more information on our ADMET & PK capabilities
please contact us. |
An
early appreciation of ADMET is critical to productivity
in discovery research. |
|